

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 June 2025 (26.06.2025)



(10) International Publication Number
WO 2025/132542 A1

(51) International Patent Classification:

A61P 25/18 (2006.01) C07D 513/14 (2006.01)
C07D 291/08 (2006.01) C07D 519/00 (2006.01)
C07D 513/04 (2006.01) A61K 31/395 (2006.01)

(21) International Application Number:

PCT/EP2024/087045

(22) International Filing Date:

18 December 2024 (18.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

PCT/EP2023/086734

19 December 2023 (19.12.2023) EP

(71) Applicant: **IDORSIA PHARMACEUTICALS LTD**
[CH/CH]; Hegenheimermattweg 91, 4123 Allschwil (CH).

(72) Inventors: **BEZENCON, Olivier**; c/o Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123 Allschwil (CH). **CHEVILLARD, Florent**; c/o Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123 Allschwil (CH). **HELL, Sandrine**; c/o Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123 Allschwil (CH). **PETERS, Jens-Uwe**; c/o Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123 Allschwil (CH). **POZZI, Davide**; c/o Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123 Allschwil (CH). **SIEGRIST, Romain**; c/o Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123 Allschwil (CH). **SURIVET, Jean-Philippe**; c/o Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123 Allschwil (CH).

(74) Agent: **VELKER, Jörg**; Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, 4123 Allschwil (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,

MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available):

ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).


Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))

(54) Title: MACROCYCLIC OREXIN AGONISTS



(I)

(57) Abstract: The present invention relates to aryl thiol macrocycles of Formula (I) wherein R¹, R², R^{A1}, X¹, X², X³, X⁴, L, X⁵, and Ring A are as described in the description, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more compounds of Formula (I), and their use as agonists of the orexin-2 receptor.

WO 2025/132542 A1